Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus. Progressive requirement for multiple therapies (UKPDS 49)

Journal of the American Medical Association

Volumn 281, Issue 21, 1999, Pages 2005-2012

  Turner, Robert C ^a   Cull, Carole A ^a   Frighi, Valeria ^a   Holman, Rury R ^a  

^a RADCLIFFE INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROPAMIDE; GLIBENCLAMIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; METFORMIN; SULFONYLUREA DERIVATIVE;

ADULT; AGE; AGED; ARTICLE; BODY MASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC DIET; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL; UNITED KINGDOM;

ADULT; BLOOD GLUCOSE; COMBINED MODALITY THERAPY; DIABETES MELLITUS, TYPE 2; DIET, FAT-RESTRICTED; DIETARY CARBOHYDRATES; DIETARY FIBER; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; LOGISTIC MODELS; MALE; METFORMIN; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDIES; SULFONYLUREA COMPOUNDS;

EID: 0032983666     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.281.21.2005     Document Type: Article

References (30)

1. 1c) to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial. Diabetes. 1995;44:968-983.
2. Reichard P, Berglund B, Britz A, Cars I, Nilsson BY, Rosenqvist U. Intensified conventional insulin treatment retards the microvascular complications of insulin-dependent diabetes mellitus (IDDM): the Stockholm Diabetes Intervention Study (SDIS) after 5 years. J Intern Med. 1991;230:101-108.
3. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995;28:103-117.
4. UKPDS Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352: 837-853.
5. Pettitt DJ, Knowler WC, Lisse JR, Bennett PH. Development of retinopathy and proteinuria in relation to plasma glucose concentration in Pima Indians. Lancet. 1980;2:1050-1052.
6. Jarrett RI, Keen H, McCartney P. The Whitehall study: 10-year follow-up report on men with impaired glucose tolerance with reference to worsening to diabetes and predictors of death. Diabet Med. 1984;1:279-283.
7. McCance DR, Hanson RL, Charles MA, et al. Comparison of tests for glycated haemoglobin and fasting and two hour plasma glucose concentrations as diagnostic methods for diabetes. BMJ. 1994;308: 1323-1328.
8. 1c levels for diagnosing diabetes: diagnostic criteria and performance revisited. Diabetes Care. 1997;20:785-791.
9. American Diabetes Association. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 1998;21(suppl 1):S5-S19.
10. Holman RR, Turner RC. Optimizing blood glucose control in type 2 diabetes: an approach based on fasting blood glucose measurements. Diabet Med. 1988;5:582-588.
11. American Diabetes Association. Clinical practice recommendations 1995. Diabetes Care. 1995;18 (suppl 1):S1-S96.
12. UKPDS Group. UK Prospective Diabetes Study VIII: study design, progress and performance. Diabetologia. 1991;34:877-890.
13. UKPDS Group. UK Prospective Diabetes Study 16: overview of six years' therapy of type 2 diabetes - a progressive disease. Diabetes. 1995;44:1249-1258.
14. UKPDS Group. UKPDS 25: clinical value of ICA and GADA in predicting insulin requirement in patients with newly diagnosed NIDDM at different ages. Lancet 1997;350:1288-1293.
15. UKPDS Group. UKPDS 28: a randomised trial of efficacy of early addition of metformin in sulphonylurea-treated non-insulin dependent diabetes. Diabetes Care. 1998;21:87-92.
16. UKPDS Group. UK Prospective Diabetes Study XI: biochemical risk factors in type 2 diabetic patients at diagnosis compared with age-matched normal subjects. Diabet Med. 1994;11:534-544.
17. Cull CA, Manley SE, Stratton IM, et al. Approach to maintaining comparability of biochemical data during long-term clinical trials. Clin Chem. 1997;43:1913-1918.
18. SAS Institute. Statistical Analysis System. 6th ed. Cary, NC: SAS Institute; 1990.
19. UKPDS Group. UK Prospective Diabetes Study 13: relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ. 1995;310:83-88.
20. UKPDS Group. UK Prospective Diabetes Study 17: a nine-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus. Ann Intern Med. 1996;124:136-145.
21. Kumar S, Boulton AJ, Beck-Nielsen H, et al, for the Troglitazone Study Group. Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Diabetologia. 1996;39:701-709.
22. Ghazzi MN, Perez JE, Antonucci TK, et al, for the Troglitazone Study Group. Cardiac and glycaemic benefits of troglitazone treatment in NIDDM. Diabetes. 1997;46:433-439.
23. Holman RR, Turner RC. Basal normoglycaemia attained with chlorpropamide in mild diabetes. Metab Clin Exp. 1978;27:539-547.
24. Abraira C, Colwell JA, Nuttall FQ. Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VACSDM): results of the Feasibility Trial. Diabetes Care. 1995;18:1113-1123.
25. Cusi K, Cunningham GR, Comstock JP. Safety and efficacy of normalizing fasting glucose with bedtime NPH insulin alone in NIDDM. Diabetes Care. 1995; 18:843-851.
26. Henry RR, Gumbiner B, Ditzler T, Wallace P, Lyon R, Glauber HS. Intensive conventional insulin therapy for type II diabetes: metabolic effects during a 6 month outpatient trial. Diabetes Care. 1993;16:21-31.
27. Birkeland KI, Rishaug U, Hanssen KE, Vaaler S. NIDDM: a rapid progressive disease: results from a long-term, randomised, comparative study of insulin or sulphonylurea treatment. Diabetologia. 1996;39: 1629-1633.
28. Yki-Jārvinen H, Kauppila M, Kujansuu E, et al. Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus. N Engl J Med. 1992;327:1426-1433.
29. Chow CC, Tsang LWW, Sorensen JP. Comparison of insulin with or without continuation of oral hypoglycaemic agents in the treatment of secondary failure in NIDDM patients. Diabetes Care. 1995;18:307-314.
30. Hayward RA, Manning WC, Kaplan SH, Wagner EH, Greenfield S. Starting insulin therapy in patients with type 2 diabetes. JAMA. 1997;278:1663-1700.